Pharmacogenomics of azathioprine and 6-mercaptopurine in gastroenterologic therapy

Reviews in Gastroenterological Disorders

Volumn 3, Issue 3, 2003, Pages 150-157

  Baker, Danial E ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

6 mercaptopurine; Azathioprine; Pharmacogenetics; Polymorphism; Thiopurine methyltransferase

Indexed keywords

ALLOPURINOL; AZATHIOPRINE; DRUG METABOLITE; MERCAPTOPURINE; THIOPURINE METHYLTRANSFERASE; TRASTUZUMAB;

ABDOMINAL PAIN; ACUTE PANCREATITIS; BLOOD TOXICITY; BONE MARROW SUPPRESSION; DISEASE SEVERITY; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG COST; DRUG ELIMINATION; DRUG INDUCED DISEASE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME POLYMORPHISM; GASTROENTEROLOGY; GASTROINTESTINAL TOXICITY; GENOTYPE; HEALTH CARE COST; HUMAN; LEUKOCYTE COUNT; LEUKOPENIA; LIVER TOXICITY; MALIGNANT NEOPLASTIC DISEASE; NAUSEA; PANCYTOPENIA; PHARMACOGENOMICS; REVIEW; VOMITING;

6-MERCAPTOPURINE; AZATHIOPRINE; CLINICAL TRIALS; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL DISEASES; GENETIC SCREENING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 0042884260     PISSN: 1533001X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Alvan G. Genetic polymorphisms in drug metabolism. J Intern Med. 1992;231:571-573.
2. Schwartz JB. Pharmacogenetics: has it reached the clinic? J Gend Specif Med. 2002;5:13-18.
3. Schreiber S, Hampe J, Eickhoff H, Lehrach H. Functional genomics in gastroenterology. Gut. 2000;47:601-607.
4. Weinshilboum R. Inheritance and drug response. N Engl J Med. 2003;348:529-537.
5. Evans WE, McLeod HL. Pharmacogenomics -drug disposition, drug targets, and side effects. N Engl J Med. 2003;348:538-549.
6. Goldstein DB. Pharmacogenetics in the laboratory and the clinic. N Engl J Med. 2003;348:553-556.
7. Genentech. Package literature for Herceptin. August 2002 (http://www.genentech.com/gene/ products/information/oncology/herceptin/insert.jsp)
8. Cuffari C, Hunt S, Bayless TM. Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy. Aliment Pharmacol Ther. 2000;14:1009-1014.
9. Armstrong VW, Oellerich M. New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine. Clin Biochem. 2001;34:9-16.
10. Arnott IDR, Watts D, Satsangi J. Azathioprine and anti-TNFalpha therapies in Crohn's disease: a review of pharmacology, clinical efficacy and safety. Pharmacol Res. 2003;47:1-10.
11. Siva C, Yokoyama WM, McLeod HL. Pharmacogenetics in rheumatology: the prospects and limitations of an emerging field. Rheumatology. 2002;41:1273-1279.
12. Corominas H, Domenech M, Gonzalez D, et al. Allelic variants of the thiopurine S-methyltransferase deficiency in patients with ulcerative colitis and in healthy controls. Am J Gastroenterol 2000;95:2313-2317.
13. McLeod HL, Siva C. The thiopurine S-methyltransferase gene locus-implications for clinical pharmacogenomics. Pharmacogenomics 2002;3:89-98.
14. Campbell S, Kingstone K, Ghosh S. Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low-dose azathioprine. Aliment Pharmacol Ther. 2002;16:389-398.
15. Coulthard SA, Hall AG. Recent advances in the pharmacogenomics of thiopurine methyltransferase. Pharmacogenomics J 2001;1:254-261.
16. Lennard L, Lilleyman JS. Individualizing therapy with 6-mercaptopurine and 6-thioguanine related to the thiopurine methyltransferase genetic polymorphism. Ther Drug Monit. 1996;18:328-334.
17. Gardiner SJ, Begg EJ, Barclay ML, Kirkpatrick CM. Genetic polymorphism and outcomes with azathioprine and 6-mercaptopurine. Adverse Drug React Toxicol Rev. 2000;19:293-312.
18. Seki T, Tanaka T, Nakamura Y. Genomic structure and multiple single-nucleotide polymorphisms (SNPs) of the thiopurine S-methyltransferase (TPMT) gene. J Hum Genet. 2000;45:299-302.
19. Schutz E, Gummert J, Mohr F, Oellerich M. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet. 1993;341:436.
20. Leipold G, Schutz E, Haas JP, Oellerich M. Azathioprine-induced severe pancytopenia due to a homozygous two-point mutation of the thiopurine methyltransferase gene in a patient with juvenile HLA-B-27-associated spondylarthritis. Arthritis Rheum. 1997;40:1896-1898.
21. Schutz E, Gummert J, Mohr FW, et al. Should 6-thioguanine nucleotides be monitored in heart transplant recipients given azathioprine? Ther Drug Monit. 1996;18:228-233.
22. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Phamacol Ther. 1989;46:149-154.
23. Weinshilboum RM, Otterness DM, Szumlanski CL. Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu Rev Pharmacol Toxicol. 1999;39:19-52.
24. Lennard L, Van Loon JA, Lilleyman JS, Weinshilboum RM. Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther. 1987;41:18-25.
25. Snow JL, Gibson LE. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Arch Dermatol. 1995;131:193-197.
26. Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet. 1990;336:225-229.
27. Chocair PR, Duley JA, Sabbaga E, et al. Fast and slow methylators: do racial differences influence risk of allograft rejection? Q J Med. 1993;86:359-363.
28. Schutz E, von Ahsen N, Oellerich M. Genotyping of eight thiopurine methyltransferase deficiency mutations: three-color multiplexing "two-color/shared" anchor, and fluorescence quenching hybridization probe assays based on thermodynamic nearest-neighbor probe designs. Clin Chem. 2000;46:1728-1737.
29. Krynetski EY, Evans WE. Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S-methyltransferase paradigm. Pharm Res. 1999;16:342-349.
30. Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med. 1997;126:608-614.
31. GlaxoSmithKline. Package literature for Purinethol. November 2002.
32. Prometheus Laboratories. Package literature for Imuran. February 2003. (http://www.prometheuslabs.com/pi/Imuran.pdf)
33. Schwab M, Schaffeler E, Marx C, et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics. 2002;12:429-436.
34. Anstey A, Lennard L, Mayou SC, Kirby JD. Pancytopenia related to azathioprine-an enzyme deficiency caused by a common genetic polymorphism: a review. J Royal Soc Med. 1992;85:752-756.
35. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000;118:705-713.
36. Lesko LJ. Pharmacogenetics: improvement of existing drug treatments. Presentation to the Food and Drug Administration's Clinical Pharmacology Subcommittee Advisory Committee for Pharmaceutical Sciences. Rockville, MD: April 22-23, 2003. (http://www.fda.gov/ohrms/dockets/ac/03/slide s/3947s2.htm) Accessed on April 22, 2003.
37. Tavadia SMB, Mydlarski PR, Reis MD, et al. Screening for azathioprine toxicity: a pharmacoeconomic analysis based on a target case. J Am Acad Dermatol. 2000;42:628-632.
38. Marra CA, Esdaile JM, Anis AH. Practical pharmacogenetics: the cost effectiveness of screening for thiopurine S-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. J Rheumatol. 2002;29:2507-2512.